Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Centessa Pharmaceuticals ( (CNTA) ).
On June 20, 2025, Centessa Pharmaceuticals held its Annual General Meeting, where all matters submitted to a vote were approved, including the re-appointment of directors and auditors. The meeting established a quorum with 124,956,837 shares represented, and key resolutions included the authorization of the Audit Committee to determine auditors’ remuneration and the approval of the Directors’ Remuneration Policy.
The most recent analyst rating on (CNTA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Average Trading Volume: 975,229
Technical Sentiment Signal: Hold
Current Market Cap: $1.69B
See more data about CNTA stock on TipRanks’ Stock Analysis page.